(Q43507658)

24 November 2017

title

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease (English)

1 reference

24 November 2017

1 reference

1 reference

4

Poewe W

1 reference

24 November 2017

Luginger E

1

1 reference

24 November 2017

Wenning GK

series ordinal

2

1 reference

24 November 2017

Bösch S

series ordinal

3

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

24 November 2017

1 reference

24 November 2017

volume

15

1 reference

24 November 2017

issue

5

1 reference

24 November 2017

page(s)

873-878

1 reference

Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Posteroventral medial pallidotomy in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Effect of GPi pallidotomy on motor function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Opposite motor effects of pallidal stimulation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Therapeutic brain concentration of the NMDA receptor antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Pain in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C873%3A%3AAID-MDS1017%3E3.0.CO%3B2-I

10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference